Abstract:Achondroplasia is the most common form of human dwarfism caused by mutations in the FGFR3 receptor tyrosine kinase. Current therapy begins at two years of age and improves longitudinal growth but does not address the cranial malformations including midface hypoplasia and foramen magnum stenosis, which lead to significant otolaryngeal and neurologic compromise. A recent clinical trial found partial restoration of cranial defects with therapy starting at 3 months of age, but results are still inconclusive. The benefits of achondroplasia therapy are therefore controversial, increasing skepticism among the medical community and patients. We used a mouse model of achondroplasia to test treatment protocols aligned with human studies. Early postnatal treatment (from day 1) was compared to late postnatal treatment (from day 4, equivalent to ~5 months in humans). Animals were treated with the FGFR3 inhibitor infigratinib and the effect on skeleton was thoroughly examined. We show that premature fusion of the skull base synchondroses occurs immediately after birth and leads to defective cranial development and foramen magnum stenosis in the mouse model to achondroplasia. This phenotype appears significantly restored by early infigratinib administration when compared to late treatment, which provides weak to no rescue. In contrast, the long bone growth is similarly improved by both early and late protocols. We provide clear evidence that immediate postnatal therapy is critical for normalization of skeletal growth in both the cranial base and long bones and the prevention of sequelae associated with achondroplasia. We also describe the limitations of early postnatal therapy, providing a paradigm-shifting argument for the development of prenatal therapy for achondroplasia.

Advances in the mechanism and therapies of achondroplasia

New treatments for children with achondroplasia

Review of published 467 achondroplasia patients: clinical and mutational spectrum

Defective Lysosomal Targeting of Activated Fibroblast Growth Factor Receptor 3 in Achondroplasia.

Achondroplasia current concept of orthopaedic management

Molecular therapeutic strategies for FGFR3 gene-related skeletal dysplasia

Meclozine and growth hormone ameliorate bone length and quality in experimental models of achondroplasia

Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia.

Gly369Cys Mutation in Mouse FGFR3 Causes Achondroplasia by Affecting Both Chondrogenesis and Osteogenesis.

Mutant Activated FGFR3 Impairs Endochondral Bone Growth by Preventing SOX9 Downregulation in Differentiating Chondrocytes.

Progress on growth promoting therapies other than growth hormone.

Evaluation of FGFR inhibitor ASP5878 as a drug candidate for achondroplasia

A Ser(365)-->Cys Mutation of Fibroblast Growth Factor Receptor 3 in Mouse Downregulates Ihh/PTHrP Signals and Causes Severe Achondroplasia.

Research on X-linked Growth Hormone Deficiency and Related Genes

Roles of FGF signaling in skeletal development and human genetic diseases.

Activation of Statl by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism

FGFR3 Induces Degradation of BMP Type I Receptor to Regulate Skeletal Development.

Low–dose infigratinib increases bone growth and corrects growth plate abnormalities in an achondroplasia mouse model

Review of patients with achondroplasia: a single-center's experience with follow-up and associated morbidities

Achondroplasia: aligning mouse model with human clinical studies shows crucial importance of immediate postnatal start of the therapy

Chinese Achondroplasia is Also Defined by Recurrent G380R Mutations of the Fibroblast Growth Factor Receptor-3 Gene